Floatz logo

Photofrin II

Pleural Disorder

Roswell Park Cancer InstitutemixturePhase 1Active
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Pleural Disorder cohort.

Asset / SponsorPhaseRating
Zactima
M.D. Anderson Cancer Center
Phase 2CCC
CIS-DIAMMINEDICHLOROPLATINUM II
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2CCC
m701 pleural infusion
Wuhan YZY Biopharma Co., Ltd.
Phase 1/2CCC
Wsk-Im02
WestVac Biopharma Co., Ltd.
Phase 1CC

Same molecule, other indications

Photofrin II is also rated in:

non-small cell lung carcinomaDormant
B
Indicative ·
63 / 100
View asset →
central nervous system neoplasmDormant
B
Indicative ·
62 / 100
View asset →
extrahepatic bile duct carcinomaDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →